Jul. 30 at 12:58 PM
$NAMS $23.78 bid. DAC (dollar average cost includes partial SELL at profit to reduce net long position from
$18.50 (11.20.24).
$17.675.
CHANGE EXIT TO
$30.00 from
$45.00 with removal of Legacy Holding status
UPDATE: Announces full data from the prespecified Alzheimer’s disease biomarker analysis in the BROADWAY clinical trial .
^ Pre-specified analysis shows obicetrapib significantly reduced absolute levels of plasma p-tau217, a key biomarker of Alzheimer's disease pathology, in both the full analysis set (p=0.0019) and in ApoE4 carriers (p=0.0215), supporting CETP inhibition as a potential novel, upstream approach to Alzheimer's prevention.
^ In APOE4/E4 carriers, the highest risk category for Alzheimer's disease, obicetrapib reduced p-tau217 levels by 20.5%, over 12 months, compared to placebo (p=0.010).
^ Results build on obicetrapib's cardiometabolic profile, including multiple clinical trials demonstrating reductions in LDL-C, small dense LDL particles, Lipoprotein(a), and biomarkers associated with diabetes and kidney function.
